Brief: Biofrontera Inc Provides Update On Patient Recruitment For Phase III Study For Treatment Of SBCC With Ameluz-PDT
01/02/2022 13:49
Feb 1 (Reuters) - Biofrontera Inc BFRI.O :
* BIOFRONTERA INC. PROVIDES UPDATE ON PATIENT RECRUITMENT
FOR
PHASE III STUDY FOR THE TREATMENT OF SBCC WITH AMELUZ®-PDT
* BIOFRONTERA INC - COMPLETION OF PATIENT RECRUITMENT
ANTICIPATED
BY END OF 2022
* BIOFRONTERA INC - TO DATE, 70% OF PLANNED 186 PATIENTS
HAVE BEEN
ENROLLED IN STUDY
Source text for Eikon: ID:nGNX17SCyn
Further company coverage: BFRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales